UBS Maintains Buy on AtriCure, Lowers Price Target to $55

AtriCure, Inc. -1.67%

AtriCure, Inc.

ATRC

28.88

-1.67%

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ: ATRC) with a Buy and lowers the price target from $60 to $55.